These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1148 related items for PubMed ID: 26356327

  • 1. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [Abstract] [Full Text] [Related]

  • 2. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
    Ramalingam P, Croce S, McCluggage WG.
    Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
    [Abstract] [Full Text] [Related]

  • 3. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
    Errichiello E, Mustafa N, Vetro A, Notarangelo LD, de Jonge H, Rinaldi B, Vergani D, Giglio SR, Morbini P, Zuffardi O.
    J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
    [Abstract] [Full Text] [Related]

  • 4. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S, Bork J, Essakly A, Alakus H, Buettner R, Hillmer AM, Bruns C, Schroeder W, Zander T, Loeser H, Gebauer F, Quaas A.
    BMC Cancer; 2020 Jan 06; 20(1):12. PubMed ID: 31906887
    [Abstract] [Full Text] [Related]

  • 5. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A, Daum O, Märkl B, Lichtmannegger I, Michal M, Hartmann A.
    Am J Surg Pathol; 2016 Apr 06; 40(4):544-53. PubMed ID: 26551623
    [Abstract] [Full Text] [Related]

  • 6. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
    Foulkes WD, Clarke BA, Hasselblatt M, Majewski J, Albrecht S, McCluggage WG.
    J Pathol; 2014 Jul 06; 233(3):209-14. PubMed ID: 24752781
    [Abstract] [Full Text] [Related]

  • 7. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
    Andrianteranagna M, Cyrta J, Masliah-Planchon J, Nemes K, Corsia A, Leruste A, Holdhof D, Kordes U, Orbach D, Corradini N, Entz-Werle N, Pierron G, Castex MP, Brouchet A, Weingertner N, Ranchère D, Fréneaux P, Delattre O, Bush J, Leary A, Frühwald MC, Schüller U, Servant N, Bourdeaut F.
    J Pathol; 2021 Sep 06; 255(1):1-15. PubMed ID: 33999421
    [Abstract] [Full Text] [Related]

  • 8. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
    Chan-Penebre E, Armstrong K, Drew A, Grassian AR, Feldman I, Knutson SK, Kuplast-Barr K, Roche M, Campbell J, Ho P, Copeland RA, Chesworth R, Smith JJ, Keilhack H, Ribich SA.
    Mol Cancer Ther; 2017 May 06; 16(5):850-860. PubMed ID: 28292935
    [Abstract] [Full Text] [Related]

  • 9. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
    Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG.
    Histopathology; 2016 Nov 06; 69(5):727-738. PubMed ID: 27100627
    [Abstract] [Full Text] [Related]

  • 10. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R, Ghosh Halder T, Weston A, Thode T, Drenner K, Lewis R, Kaadige MR, Srivastava S, Daniel Ampanattu S, Rodriguez Del Villar R, Lang J, Vankayalapati H, Weissman B, Trent JM, Hendricks WPD, Sharma S.
    PLoS One; 2020 Nov 06; 15(7):e0235705. PubMed ID: 32649682
    [Abstract] [Full Text] [Related]

  • 11. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q, Xia QY, Wang ZY, Li L, Shen Q, Shi SS, Wang X, Liu B, Wang YF, Shi QL, Ma HH, Lu ZF, He Y, Zhang RS, Yu B, Zhou XJ.
    Histopathology; 2015 Jul 06; 67(1):121-9. PubMed ID: 25496315
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, Gay LM, Ali SM, Elvin JA.
    Gynecol Oncol; 2017 Dec 06; 147(3):626-633. PubMed ID: 29102090
    [Abstract] [Full Text] [Related]

  • 13. Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.
    Orlando KA, Douglas AK, Abudu A, Wang Y, Tessier-Cloutier B, Su W, Peters A, Sherman LS, Moore R, Nguyen V, Negri GL, Colborne S, Morin GB, Kommoss F, Lang JD, Hendricks WP, Raupach EA, Pirrotte P, Huntsman DG, Trent JM, Parker JS, Raab JR, Weissman BE.
    Elife; 2020 Dec 23; 9():. PubMed ID: 33355532
    [Abstract] [Full Text] [Related]

  • 14. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, Warth A, Agaimy A.
    Ann Diagn Pathol; 2017 Feb 23; 26():47-51. PubMed ID: 28038711
    [Abstract] [Full Text] [Related]

  • 15. SMARCA4-deficient undifferentiated carcinoma of the ovary (small cell carcinoma, hypercalcemic type): clinicopathologic and immunohistochemical study of 3 cases.
    Agaimy A, Thiel F, Hartmann A, Fukunaga M.
    Ann Diagn Pathol; 2015 Oct 23; 19(5):283-7. PubMed ID: 26123103
    [Abstract] [Full Text] [Related]

  • 16. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, Roberts CW.
    Mol Cell Biol; 2014 Mar 23; 34(6):1136-44. PubMed ID: 24421395
    [Abstract] [Full Text] [Related]

  • 17. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
    Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.
    J Pathol; 2017 Jul 23; 242(3):371-383. PubMed ID: 28444909
    [Abstract] [Full Text] [Related]

  • 18. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
    Strehl JD, Wachter DL, Fiedler J, Heimerl E, Beckmann MW, Hartmann A, Agaimy A.
    Ann Diagn Pathol; 2015 Aug 23; 19(4):198-202. PubMed ID: 25920939
    [Abstract] [Full Text] [Related]

  • 19. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS, Fuchs TL, Clarkson A, Sheen A, Sioson L, Chou A, Gill AJ.
    Histopathology; 2022 May 23; 80(6):906-921. PubMed ID: 34951482
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.